Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALI study: DOAC levels prior to incision
NL-OMON55427Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban, rivaroxaban and dabigatran in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (3 arms), sponsored by Leiden University Medical Center. Primary endpoint: Preoperative DOAC level by LC-MS. Started May 2019; status: completed.
02
Drugs
apixabanrivaroxabandabigatran
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON55427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55427.